Modulation of Arachidonic Acid Metabolism by Olsalazine and Other Aminosalicylates in Leukocytes

References

• Rampton D S, Hawkey C J. Prostaglandins and ulcerative colitis. Gut 1984; 25: 1399–1413
   PubMed Web of Science ®Google Scholar
• Peskar B M, Dreyling K W, May B, Thieves M, Morgenroth K. Increased formation of leukotriene B4 and sulphidopeptide-leukotrienes by rectal mucosa of patient with Crohn's disease and ulcerative colitis. Gut 1985; 26: 542–543
   Google Scholar
• Sharon P, Stenson W F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86: 453–460
   PubMed Web of Science ®Google Scholar
• Ford-Hutchinson A W. Leukotrienes: their formation and role as inflammatory mediators. Fed Proc 1985; 44: 25–29
   PubMedGoogle Scholar
• Nielsen O H, Elmgreen J. Activation of neutrophil chemotaxis by leukotriene B4 and 5-hydroxyeicosa-tetraenoic acid in chronic inflammatory bowel disease. Scand J Clin Lab Invest 1987; 47: 605–611
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988; 29: 1316–1321
   PubMed Web of Science ®Google Scholar
• Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachnilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81: 444–449
   PubMed Web of Science ®Google Scholar
• Peskar B M, Dreyling K W, Peskar B A, May B, Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions 1986; 18: 381–383
   PubMedGoogle Scholar
• Smith P R, Dawson D J, Swan C HJ. Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone. Gut 1978; 20: 802–805
   Google Scholar
• Hetzel D J, Shearman D JC, Bochner F, Imhoff D M, Gibson G E. Azodisalicylate (olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. J Gastroenterol Hepatol 1986; 1: 257–266
   Web of Science ®Google Scholar
• Meyers S, Sachar D B, Present D H, Janowitz H D. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Scand J Gastroenterol 1988; 23: 29–37
   Web of Science ®Google Scholar
• Selby W S, Barr G D, Ireland A, Mason C H, Jewell D P. Olsalazine in active ulcerative colitis. Br Med J 1985; 291: 1373–1375
   PubMed Web of Science ®Google Scholar
• Sandberg-Gertzen H, Järnerot G, Kraaz W. Azo-disal sodium in the treatment of ulcerative colitis. Gastroenterology 1986; 90: 1024–1030
   PubMed Web of Science ®Google Scholar
• Willoughby C P, Cowan R E, Gould S R, Machell R J, Stewart J B. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand J Gastroenterol 1988; 23: 40–44
   Web of Science ®Google Scholar
• Ireland A, Mason C H, Jewell D P. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835–837
   PubMed Web of Science ®Google Scholar
• Das K M, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmakokinet 1976; 1: 406–425
   Google Scholar
• Lauritsen K, Hansen J, Ryde M, Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984; 86: 1496–1500
   PubMed Web of Science ®Google Scholar
• Willoughby C P, Aronson J K, Agback H, Bodin N O, Truelove S C. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 1982; 23: 1081–1087
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Lauren L S, Bukhave K, Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's oilitis. Gut 1988; 29: 974–982
   PubMed Web of Science ®Google Scholar
• Azad Khan A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892–895
   PubMed Web of Science ®Google Scholar
• Wallace J L, MacNaughton W K, Morris G P, Beck P L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96: 29–36
   PubMed Web of Science ®Google Scholar
• Allgayer H, Stenson W F. Lipoxygenasehemmung im Tiermodell einer Colitis: ein mögliches thera-peutisches Prinzip. Z Gastroenterol 1988; 26: 534
   Google Scholar
• Peskar B M, Dreyling K W, May B, Schaarschmidt K, Goebell H. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 51S–56S
   Google Scholar
• Molin L, Stendahl O. The effect of sulfasalzine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand 1979; 206: 451–457
   PubMedGoogle Scholar
• Neal T M, Winterbourn C C, Vissers M C. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-amino-salicylic acid, sulfapyridine and olsalazine. Biochem Pharmacol 1987; 36: 2765–2768
   PubMed Web of Science ®Google Scholar
• Ahnfelt-Ronne I, Nielsen O H. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 1987; 21: 191–194
   PubMedGoogle Scholar
• Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28: 190–195
   PubMed Web of Science ®Google Scholar
• Gould S R, Brash A R, Conolly M E, Lennard-Jones J E. Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Med 1981; 6: 165–182
   PubMedGoogle Scholar
• Campieri M, Lanfranchi G A, Bazzocchi G, Brignola C, Benatti A. Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 1980; 78: 193
   PubMed Web of Science ®Google Scholar
• Rampton D S, McNeil N I, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983; 24: 187–189
   PubMed Web of Science ®Google Scholar
• Nielsen O H, Bukhave K, Elmgreen J, Ahnfelt-Ronne I. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 577–582
   PubMed Web of Science ®Google Scholar
• Allgayer H, Stenson W F. A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid. Immunopharmacology 1988; 15: 39–46
   Google Scholar
• Dajani E Z, Agrawal N M. Protective effects of prostaglandins against nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Int J Clin Pharmacol Res 1989; 9: 359–369
   Google Scholar
• Hjorth R, Jonsson A K, Vretblad P. A rapid method for purification of human granulocytes using Percoll R. A comparison with dextran sedimentation. J Immunol Methods 1981; 43: 95–101
   PubMed Web of Science ®Google Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Boughton-Smith N K, Hawkey C J, Whittle B J. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa. Gut 1983; 24: 1176–1182
   PubMed Web of Science ®Google Scholar
• Preclik G, Stange E F, Gerber K, et al. Effect of antacid treatment on endogenous prostaglandin synthesis in human antral and duodenal mucosa. Dig Dis Sci 1989; 34: 1860–1864
   Google Scholar
• Preclik G, Stange E F, Arnold D, Ditschuneit H. In vitro effects of arachidonic acid on the prostaglandin synthesizing system in gastric mucosa. Prostaglandins 1991; 41: 359–373
   Google Scholar
• Preclik G, Stange E F, Arnold D, Kraft O, Schneider A, Ditschuneit H. Prostaglandin synthesis along the gastrointestinal tract of the rabbit: differences in total synthesis and profile. Prostaglandins 1987; 33: 459–477
   Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65–70
   Web of Science ®Google Scholar
• Nielsen O H, Ahnfelt-Ronne I, Elmgreen J. Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils. Gut 1987; 28: 181–185
   PubMed Web of Science ®Google Scholar
• Furukawa M, Joshimoto T, Ochi K, Yamamoto S. Studies of arachidonate 5-lipoxygenase of rat basophilic leukemia cells. Biochim Biophys Acta 1984; 795: 458–465
   PubMedGoogle Scholar
• Jakschik B A, Kuo C G. Characterization of leukotriene A4 and B4 biosynthesis. Prostaglandins 1983; 25: 767–782
   Google Scholar
• Sun F F, McGuire J C. Metabolism of arachidonic acid by human neutrophils. Characterization of the enzymatic reactions that lead to the synthesis of Ieucotriene B4. Biochim Biophys Acta 1984; 794: 56–64
   PubMedGoogle Scholar
• Ahlquist D A, Madson T H, Romero J C, Dozois R R, Malagelada J R. Factors influencing metabolism of arachidonic acid in guinea pig gastric mucosa. Am J Physiol 1983; 244: G131–G137
   Google Scholar
• Marshall P J, Kulmacz R J, Lands W E. Constraints on prostaglandin biosynthesis in tissues. J Biol Chem 1987; 262: 3510–3517
   PubMed Web of Science ®Google Scholar
• Ryde M, Sandberg-Gertzen H, Järnerot G, Lauritsen K, Rask-Madsen J. Is 5-aminosalicylic acid delivered directly to the colon by olsalazine?. Scand J Gastroenterol 1988; 23: 104–106
   Web of Science ®Google Scholar
• Sircar J C, Schwender C F, Carethers M E. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol 1983; 32: 170–172
   PubMed Web of Science ®Google Scholar
• Stenson W F, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494–497
   PubMed Web of Science ®Google Scholar
• Hawkey C J, Boughton-Smith N K, Whittle B J. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985; 30: 1161–1165
   PubMed Web of Science ®Google Scholar
• Sharon P, Stenson W F. Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease. Gastroenterology 1985; 88: 55–63
   PubMed Web of Science ®Google Scholar
• Hoult J RS, Moore P K. Sulphasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Br J Pharmacol 1978; 64: 6–8
   Google Scholar
• Pacheco S, Hillier K, Smith C L. Inflammatory bowel disease: the in vitro effect of sulphasalazine and other agents on prostaglandin synthesis by human rectal mucosa. Braz J Med Biol Res 1987; 20: 221–230
   Google Scholar
• Rachmilewitz D, Ligumsky M, Haimovitz A, Treves A. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel. Gastroenterology 1982; 82: 673–679
   Google Scholar
• Stenson W F, Lobos E. Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol 1981; 32: 2205–2209
   Google Scholar
• Boughton-Smith N K, Hawkey C J, Whittle B JR. Sulphasalazine and the inhibition of thromboxane synthesis in human colonic mucosa. Br J Pharmacol 1983; 80: 604
   Google Scholar
• Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638–640
   Google Scholar
• Kolassa N, Becker R, Wiener H. Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa. Prostaglandins 1985; 29: 133–142
   PubMedGoogle Scholar
• Schlenker T, Peskar B M. Dual effect of sulphasalazine on colonic prostaglandin synthetase. Lancet 1981; 2: 815
   Google Scholar
• Hawkey C J, Truelove S C. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 1983; 24: 213–217
   PubMed Web of Science ®Google Scholar
• Boughton-Smith N K, Wallace J L, Morris G P, Whittle B JR. The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease. Br J Pharmacol 1988; 94: 65–72
   PubMed Web of Science ®Google Scholar
• Carlin G, Djursäter R, Smedegard G, Gerdin B. Effect of anti-inflammatory drugs on xanthine oxidase and xanthine oxidase induced depolymerization of hyluronic acid. Agents Actions 1985; 16: 377–384
   PubMedGoogle Scholar
• Kulmacz R J. Prostaglandin H synthase and hydroperoxides: peroxidase reaction and inactivation kinetics. Arch Biochem Biophys 1986; 249: 273–285
   PubMed Web of Science ®Google Scholar
• Ogino N, Miyamoto T, Yamamoto S, Hayaishi O. Prostaglandin endoperoxide E isomerase from bovine vesicular gland microsomes, a glutathione-requiring enzyme. J Biol Chem 1977; 252: 890–895
   PubMed Web of Science ®Google Scholar
• Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; 97: 77–89
   Google Scholar
• Chan J A, Nagasawa M, Takeguchi C, Sih C J. On agents favouring prostaglandin F formation during biosynthesis. Biochemistry 1975; 14: 2987–2991
   PubMed Web of Science ®Google Scholar